Which adverse effect is associated with amylin mimetics?

Which adverse effect is associated with amylin mimetics?

• A. Severe hypoglycemia risk
• B. Delays PO drug absorption
• C. Nausea and vomiting
• D. Headache

Answer: (A)

Amylin mimetics act like natural amylin, slowing gastric emptying, suppressing glucagon, and promoting satiety. Because they slow the rate at which the stomach empties, they blunt the post-meal rise in blood glucose. When these agents are used with insulin, especially mealtime insulin, their glucose-lowering effects add to insulin’s action. That combination can lead to significant drops in glucose levels, i.e., severe hypoglycemia. This risk is why hypoglycemia is highlighted as a key adverse effect for amylin mimetics in combination therapy, and why careful insulin dose adjustments and glucose monitoring are required when starting therapy. Nausea and vomiting are also common due to slowed gastric motility, and the delayed gastric emptying can slow absorption of other oral medications, but the most clinically important adverse effect to watch for in practice is the potential for severe hypoglycemia when an amylin mimetic is used with insulin.

Amylin mimetics act like natural amylin, slowing gastric emptying, suppressing glucagon, and promoting satiety. Because they slow the rate at which the stomach empties, they blunt the post-meal rise in blood glucose. When these agents are used with insulin, especially mealtime insulin, their glucose-lowering effects add to insulin’s action. That combination can lead to significant drops in glucose levels, i.e., severe hypoglycemia. This risk is why hypoglycemia is highlighted as a key adverse effect for amylin mimetics in combination therapy, and why careful insulin dose adjustments and glucose monitoring are required when starting therapy.

Nausea and vomiting are also common due to slowed gastric motility, and the delayed gastric emptying can slow absorption of other oral medications, but the most clinically important adverse effect to watch for in practice is the potential for severe hypoglycemia when an amylin mimetic is used with insulin.